Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Heart age app trial tests digital nudge against cardiovascular disease

NCT ID NCT05827861

Prevention Sponsor: National University of Singapore Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This completed trial in Singapore tested whether telling people their 'heart age' and giving them a behavior-change app (HOPE-CVD) could lower their risk of heart disease. Over 1,100 adults aged 30-74 with at least a 5% risk were split into four groups, each receiving different levels of risk information and app support. The study measured changes in predicted heart risk, blood pressure, cholesterol, and healthy behaviors after six months.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
HeartAge risk presentation and HOPE-CVD mobile app (behavioral interventions)
What this could lead to
If successful, this approach could provide a simple, scalable way to help people lower their heart disease risk using personalized risk communication and digital behavior support.
What could go wrong
The trial is completed but results are not yet published, so we don't know if it worked. It also excluded people needing medication, so findings may not apply to higher-risk groups.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

1,121 people

The number who actually took part.

Started

May 2023

Finished

Oct 2025

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

30 to 74 years

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Aged 30-74 years; 2. Singapore citizen, or permanent resident 3. Able to read and understand English 4. Have access to and is comfortable using an internet-enabled device 5. At least 5% risk of CVD, as measured by the Framingham Risk Score (FRS), based on previous health screening results Exclusion Criteria: 1. Existing heart disease or a prior history of coronary artery disease/angina/myocardial infarction/revascularisation, transient ischaemic attack/stroke, peripheral vascular disease, heart failure and cardiac arrhythmia 2. Suffering from cancer or chronic kidney disease 3. Currently prescribed with statins, exetimibe and pcsk-9 inhibitors to treat cholesterol levels 4. Been told by a doctor that they should only do physical activity recommended by a doctor due to a heart condition 5. Serious mental illness (Eg. A patient who is suffering from serious mental illness refers to those who need assistance in daily activities due to their mental illness.) 6. The following groups of individuals will be excluded as most of them would require pharmacological therapy for risk factors based on clinical guidelines in Singapore: * Diagnosed with diabetes * For those with FRS of 5-9%, LDL ≥160mg/dL * For those with FRS of 10-19%, LDL ≥130mg/dL * For those with FRS of ≥20%, LDL ≥100mg/dL * Total cholesterol \>280 mg/dL at the point of screening * Systolic blood pressure \>160 mmHg at the point of screening * Triglycerides ≥4.5 mmol/L 7. Pregnant or planning to be pregnant in the next 7 months 8. Unable to give informed consent 9. Current or previous participants in HOPE Pilot Study, or HOPE-CVD-GP study 10. Members of the same household or family of existing enrolled participants

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Cardiovascular diseases are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

cardiovascular disorder

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Cardiovascular diseases

Contacts and locations

Locations

  • National University of Singapore

    Singapore, Singapore, 117549, Singapore

More trials for these conditions

Other studies related to the condition(s) this trial covers.